Novel pH responsive hesperidin nanoformulation exerts anticancer activity on lung adenocarcinoma cells by targeting Akt/mTOR and MEK/ERK pathways
Source abstract
Abstract
Zinc oxide nanoparticle based drug delivery enhances bioavailability of anticancer drug to the tumor site. We developed novel biocompatible ZnO nanoparticles for the targeted delivery of hesperidin. UV, FT-IR, DLS analysis, SEM and XRD analyses were done to confirm hesperidin loading onto zinc oxide nanoparticles. We also performed crystal violet staining, ROS and live-dead staining assay to check toxicity of hesperidin nanoformulation on A549 lung adenocarcinoma cells. Effect of nanoformulation on protein and gene expression was evaluated. Particle size of formulated ZnO NPs was 3 nm, which increased to 104 nm after hesperidin loading. Hesperidin nanoformulation showed enhanced anticancer, antiproliferative and antimigratory effects on A549 cells with an IC50 concentration of 40 µg/mL. The nanoformulation reduced expression of Akt/mTOR and MEK/ERK signalling proteins and increased the expression of apoptotic markers. Hesperidin nanoformulation also upregulated the expression of apoptotic genes such as Bax, p53 and decreased the expression of anti-apoptotic gene Bcl2. Hesperidin nanoformulation and its biological activities.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Synthesis and biological activity · Cell death mechanisms and regulation · Marine Sponges and Natural Products
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (62)
Show source-provided references
1. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021). https://doi.org/10.3322/caac.2166010.3322/caac.21660 ↗
2. H. Padinharayil, J. Varghese, M.C. John, G.K. Rajanikant, C.M. Wilson, M. Al-Yozbaki, K. Renu, S. Dewanjee, R. Sanyal, A. Dey, A.G. Mukherjee, Non-small cell lung carcinoma (NSCLC): implications on molecular pathology and advances in early diagnostics and therapeutics. Genes Dis. 10, 960–989 (2023). https://doi.org/10.1016/j.gendis.2022.07.02310.1016/j.gendis.2022.07.023 ↗
3. B. Melosky, K. Kambartel, M. Haentschel, M. Bennetts, D.J. Nickens, J. Brinkmann, A. Kayser, M. Moran, F. Cappuzzo, Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol. Diagn. Ther. 26, 7–18 (2022). https://doi.org/10.1007/s40291-021-00563-110.1007/s40291-021-00563-1 ↗
4. A. Leiter, R.R. Veluswamy, J.P. Wisnivesky, The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol. 20, 624–639 (2023). https://doi.org/10.1038/s41571-023-00798-310.1038/s41571-023-00798-3 ↗
5. J.A. Barta, C.A. Powell, J.P. Wisnivesky, Global epidemiology of lung cancer. Ann. Glob. Health (2019). https://doi.org/10.5334/aogh.241910.5334/aogh.2419 ↗
6. B.I. Hiddinga, J. Raskin, A. Janssens, P. Pauwels, J.P. Van Meerbeeck, Recent developments in the treatment of small cell lung cancer. Eur. Respir. Rev. (2021). https://doi.org/10.1183/16000617.0079-202110.1183/16000617.0079-2021 ↗
7. S.R. Pavan, A. Prabhu, Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: a review. J. Mater. Sci. 57, 16192–16227 (2022). https://doi.org/10.1007/s10853-022-07649-z10.1007/s10853-022-07649-z ↗
8. Q. Li, Z. Li, T. Luo, H. Shi, Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy. Mol. Med. 3, 47 (2022). https://doi.org/10.1186/s43556-022-00110-210.1186/s43556-022-00110-2 ↗
9. F. Majolo, L.K.D.O.B. Delwing, D.J. Marmitt, I.C. Bustamante-Filho, M.I. Goettert, Medicinal plants and bioactive natural compounds for cancer treatment: important advances for drug discovery. Phytochem. Lett. 31, 196–207 (2019). https://doi.org/10.1016/j.phytol.2019.04.00310.1016/j.phytol.2019.04.003 ↗
10. M. Hajialyani, M. Hosein Farzaei, J. Echeverría, S.M. Nabavi, E. Uriarte, E. Sobarzo-Sánchez, Hesperidin as a neuroprotective agent: a review of animal and clinical evidence. Molecules 24, 648 (2019). https://doi.org/10.3390/molecules2403064810.3390/molecules24030648 ↗
11. V. Aggarwal, H.S. Tuli, F. Thakral, P. Singhal, D. Aggarwal, S. Srivastava, A. Pandey, K. Sak, M. Varol, M.A. Khan, G. Sethi, Molecular mechanisms of action of hesperidin in cancer: recent trends and advancements. Exp. Biol. Med. 245, 486–497 (2020). https://doi.org/10.1177/153537022090367110.1177/1535370220903671 ↗
12. G. Mikus, K.I. Foerster, Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity. Transl. Cancer. Res. 6, 1592–1599 (2017). https://doi.org/10.21037/tcr.2017.09.1010.21037/tcr.2017.09.10 ↗
13. F.G. Baveloni, B.V. Riccio, L.D. Di Filippo, M.A. Fernandes, A.B. Meneguin, M. Chorilli, Nanotechnology-based drug delivery systems as potential for skin application: a review. Curr. Med. Chem. 28, 3216–3248 (2021). https://doi.org/10.2174/092986732766620083112565610.2174/0929867327666200831125656 ↗
14. S. Anjum, M. Hashim, S.A. Malik, M. Khan, J.M. Lorenzo, B.H. Abbasi, C. Hano, Recent advances in zinc oxide nanoparticles (ZnO NPs) for cancer diagnosis, target drug delivery, and treatment. Cancers 13, 4570 (2021). https://doi.org/10.3390/cancers1318457010.3390/cancers13184570 ↗
15. P. Sadhukhan, M. Kundu, S. Chatterjee, N. Ghosh, P. Manna, J. Das, P.C. Sil, Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy. Mater. Sci. Eng. C 100, 129–40 (2019). https://doi.org/10.1016/j.msec.2019.02.09610.1016/j.msec.2019.02.096 ↗
16. M. Kundu, P. Sadhukhan, N. Ghosh, S. Chatterjee, P. Manna, J. Das, P.C. Sil, pH-responsive and targeted delivery of curcumin via phenylboronic acid-functionalized ZnO nanoparticles for breast cancer therapy. J. Adv. Res. 18, 161–172 (2019). https://doi.org/10.1016/j.jare.2019.02.03610.1016/j.jare.2019.02.036 ↗
17. Z.M. He, P.H. Zhang, X. Li, J.R. Zhang, J.J. Zhu, A targeted DNAzyme-nanocomposite probe equipped with built-in Zn2+ arsenal for combined treatment of gene regulation and drug delivery. Sci. Rep. 6, 22737 (2016). https://doi.org/10.1038/srep2273710.1038/srep22737 ↗
18. J.S. Kim, C.H. Yun, Inhibition of human cytochrome P450 3A4 activity by zinc (II) ion. Toxicol. Lett. 156, 341–350 (2005). https://doi.org/10.1016/j.toxlet.2004.12.00610.1016/j.toxlet.2004.12.006 ↗
19. D.J. Peng, J.Y. Zhou, G.S. Wu, Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem. Biophys. Res. Commun. 394, 600 (2010). https://doi.org/10.1016/j.bbrc.2010.03.02910.1016/j.bbrc.2010.03.029 ↗
20. A.K. Garg, B. Maddiboyina, M.H. Alqarni, A. Alam, H.M. Aldawsari, P. Rawat, S. Singh, P. Kesharwani, Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system. J. Biomater. Sci. Polym. Ed. 32, 1009–1023 (2021). https://doi.org/10.1080/09205063.2021.189247110.1080/09205063.2021.1892471 ↗
21. J.W. Rasmussen, E. Martinez, P. Louka, D.G. Wingett, Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin. Drug Deliv. 7, 1063–1077 (2010). https://doi.org/10.1517/17425247.2010.50256010.1517/17425247.2010.502560 ↗
22. M.E. Davis, Z. Chen, D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771–782 (2008). https://doi.org/10.1038/nrd261410.1038/nrd2614 ↗
23. M.A.E.J. Ambrose, The surface properties of cancer cells: a review. Cancer. Res. 22, 525–548 (1962)
24. A. Degen, M. Kosec, Effect of pH and impurities on the surface charge of zinc oxide in aqueous solution. J. Eur. Ceram. Soc. 20, 667–673 (2000). https://doi.org/10.1016/S0955-2219(99)00203-410.1016/S0955-2219(99)00203-4 ↗
25. G. Sundraraman, L.S. Jayakumari, Meticulous taxifolin releasing performance by the zinc oxide nanoparticles: as a short road to drug delivery system for cancer therapeutics. J. Clust. Sci. 31, 241–255 (2020). https://doi.org/10.1007/s10876-019-01642-410.1007/s10876-019-01642-4 ↗
26. P. Sadhukhan, M. Kundu, S. Chatterjee, N. Ghosh, P. Manna, J. Das, P.C. Sil, Targeted delivery of quercetin via pH-responsive zinc oxide nanoparticles for breast cancer therapy. Mater. Sci. Eng. C 100, 129–140 (2019). https://doi.org/10.1016/j.msec.2019.02.09610.1016/j.msec.2019.02.096 ↗
27. D. Rossi, A. Zlotnik, The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217–242 (2000). https://doi.org/10.1146/annurev.immunol.18.1.21710.1146/annurev.immunol.18.1.217 ↗
28. J. Arai, M. Yasukawa, Y. Yakushijin, T. Miyazaki, S. Fujita, Stromal cells in lymph nodes attractB-lymphoma cells via production ofstromal cell-derived factor-1. Eur. J. Haematol. 64, 323–332 (2000). https://doi.org/10.1034/j.1600-0609.2000.90147.x10.1034/j.1600-0609.2000.90147.x ↗
29. K.M. Hajra, D.Y. Chen, E.R. Fearon, The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613–1618 (2002)
30. R.M. Mège, N. Ishiyama, Integration of cadherin adhesion and cytoskeleton at adherens junctions. Cold. Spring. Harb. Perspect. Boil. 9, a028738 (2017). https://doi.org/10.1101/cshperspect.a02873810.1101/cshperspect.a028738 ↗
31. S. Mahalanobish, M. Kundu, S. Ghosh, J. Das, P.C. Sil, Fabrication of phenyl boronic acid modified pH-responsive zinc oxide nanoparticles as targeted delivery of chrysin on human A549 cells. Toxicol. Rep. 9, 961–969 (2022). https://doi.org/10.1016/j.toxrep.2022.04.01710.1016/j.toxrep.2022.04.017 ↗
32. J. Wang, J.S. Lee, D. Kim, L. Zhu, Exploration of zinc oxide nanoparticles as a multitarget and multifunctional anticancer nanomedicine. ACS Appl. Mater. Interfaces 9, 39971–39984 (2017). https://doi.org/10.1021/acsami.7b1121910.1021/acsami.7b11219 ↗
33. Y.S. Bae, H. Oh, S.G. Rhee, Y.D. Yoo, Regulation of reactive oxygen species generation in cell signaling. Mol. Cells 32, 491–509 (2011). https://doi.org/10.1007/s10059-011-0276-310.1007/s10059-011-0276-3 ↗
34. P. Das, M. Maruthapandi, A. Saravanan, M. Natan, G. Jacobi, E. Banin, A. Gedanken, Carbon dots for heavy-metal sensing, pH-sensitive cargo delivery, and antibacterial applications. ACS Appl. Nano Mater. 3, 11777–11790 (2020). https://doi.org/10.1021/acsanm.0c0230510.1021/acsanm.0c02305 ↗
35. J. Alipal, S. Saidin, H.Z. Abdullah, M.I. Idris, T.C. Lee, Physicochemical and cytotoxicity studies of a novel hydrogel nanoclay EPD coating on titanium made of chitosan/gelatin/halloysite for biomedical applications. Mater. Chem. Phys. 290, 126543 (2022). https://doi.org/10.1016/j.matchemphys.2022.12654310.1016/j.matchemphys.2022.126543 ↗
36. P. Pimton, P. Ratphibun, N. Tassaneesuwan, R. Chiangnoon, P. Uttayarat, Cytotoxicity evaluation of hydrogel sheet dressings fabricated by gamma irradiation: extract and semi-direct contact tests. Trends Sci. 19, 4583–4583 (2022). https://doi.org/10.48048/tis.2022.458310.48048/tis.2022.4583 ↗
37. P. Das, S. Ganguly, A. Saha, M. Noked, S. Margel, A. Gedanken, Carbon-dots-initiated photopolymerization: an in situ synthetic approach for MXene/poly (norepinephrine)/copper hybrid and its application for mitigating water pollution. ACS Appl. Mater. Interfaces 13, 31038–31050 (2021). https://doi.org/10.1021/acsami.1c0811110.1021/acsami.1c08111 ↗
38. S. Ganguly, P. Das, E. Itzhaki, E. Hadad, A. Gedanken, S. Margel, Microwave-synthesized polysaccharide-derived carbon dots as therapeutic cargoes and toughening agents for elastomeric gels. ACS Appl. Mater. Interfaces 12, 51940–51951 (2020). https://doi.org/10.1021/acsami.0c1452710.1021/acsami.0c14527 ↗
39. C. Garrido, L. Galluzzi, M. Brunet, P.E. Puig, C. Didelot, G. Kroemer, Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13, 1423–1433 (2006). https://doi.org/10.1038/sj.cdd.440195010.1038/sj.cdd.4401950 ↗
40. C.W. Lee, C.C.Y. Huang, M.C. Chi, K.H. Lee, K.T. Peng, M.L. Fang, Y.C. Chiang, J.F. Liu, Naringenin induces ROS-mediated ER stress, autophagy, and apoptosis in human osteosarcoma cell lines. Molecules 27, 373 (2022). https://doi.org/10.3390/molecules2702037310.3390/molecules27020373 ↗
41. C.M. Pfeffer, A.T. Singh, Apoptosis: a target for anticancer therapy. Int. J. Mol. Sci. 19, 448 (2018). https://doi.org/10.3390/ijms1902044810.3390/ijms19020448 ↗
42. S. Elmore, Apoptosis: a review of programmed cell death. Toxicol. Pathol. 35, 495–516 (2007). https://doi.org/10.1080/0192623070132033710.1080/01926230701320337 ↗
43. E. Obeng, Apoptosis (programmed cell death) and its signals—a review. Braz. J. Biol. Res. 81, 1133–1143 (2020). https://doi.org/10.1590/1519-6984.22843710.1590/1519-6984.228437 ↗
44. R. Ito, M. Yashiro, T. Tsukioka, N. Izumi, H. Komatsu, H. Inoue, Y. Yamamoto, N. Nishiyama, Pyruvate dehydrogenase E1α represents a reliable prognostic predictor for patients with non-small cell lung cancer resected via curative operation. J. Thorac. Dis. 13, 5691 (2021). https://doi.org/10.21037/jtd-21-146310.21037/jtd-21-1463 ↗
45. T. McFate, A. Mohyeldin, H. Lu, J. Thakar, J. Henriques, N.D. Halim, H. Wu, M.J. Schell, T.M. Tsang, O. Teahan, S. Zhou, Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem. 283, 22700–22708 (2008)10.1074/jbc.M801765200 ↗
46. X. Wu, J. Guo, Y. Chen, X. Liu, G. Yang, Y. Wu, Y. Tian, N. Liu, L. Yang, S. Wei, H. Deng, The 60-kDa heat shock protein regulates energy rearrangement and protein synthesis to promote proliferation of multiple myeloma cells. Br. J. Haematol. 190, 741–752 (2020). https://doi.org/10.1111/bjh.1656910.1111/bjh.16569 ↗
47. Z. Wu, B. Liu, J. Liu, Q. Zhang, J. Liu, N. Chen, R. Chen, R. Zhu, Resveratrol inhibits the proliferation of human melanoma cells by inducing G1/S cell cycle arrest and apoptosis. Mol. Med. Rep. 11, 400–404 (2015). https://doi.org/10.3892/mmr.2014.271610.3892/mmr.2014.2716 ↗
48. J.T. Pai, M.W. Hsu, Y.L. Leu, K.T. Chang, M.S. Weng, Induction of G2/M cell cycle arrest via p38/p21Waf1/Cip1-dependent signaling pathway activation by bavachinin in non-small-cell lung cancer cells. Molecules 26, 5161 (2021). https://doi.org/10.3390/molecules2617516110.3390/molecules26175161 ↗
49. S. Deota, S. Rathnachalam, K. Namrata, M. Boob, A. Fulzele, S. Radhika, S. Ganguli, C. Balaji, S. Kaypee, K.K. Vishwakarma, T.K. Kundu, Allosteric regulation of cyclin-B binding by the charge state of catalytic lysine in CDK1 is essential for cell-cycle progression. J. Mol. Biol. 431, 2127–2142 (2019). https://doi.org/10.1016/j.jmb.2019.04.00510.1016/j.jmb.2019.04.005 ↗
50. R. Xia, X. Sheng, X. Xu, C. Yu, H. Lu, Hesperidin induces apoptosis and G0/G1 arrest in human non-small cell lung cancer A549 cells. Int. J. Mol. Med. 41, 464–472 (2018). https://doi.org/10.3892/ijmm.2017.325010.3892/ijmm.2017.3250 ↗
51. Z. Wen, R. Jiang, Y. Huang, Z. Wen, D. Rui, X. Liao, Z. Ling, Inhibition of lung cancer cells and Ras/Raf/MEK/ERK signal transduction by ectonucleoside triphosphate phosphohydrolase-7 (ENTPD7). Respir. Res. 20, 1–12 (2019). https://doi.org/10.1186/s12931-019-1165-010.1186/s12931-019-1165-0 ↗
52. L. Li, G.D. Zhao, Z. Shi, L.L. Qi, L.Y. Zhou, Z.X. Fu, The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol. Lett. 12, 3045–3050 (2016). https://doi.org/10.3892/ol.2016.511010.3892/ol.2016.5110 ↗
53. Y. Guo, Q.Q. Shan, P.Y. Gong, S.C. Wang, The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells. J. Cancer Ther. 14, 125–131 (2018). https://doi.org/10.4103/0973-1482.17211110.4103/0973-1482.172111 ↗
54. R. Bhanumathi, M. Manivannan, R. Thangaraj, S. Kannan, Drug-carrying capacity and anticancer effect of the folic acid-and berberine-loaded silver nanomaterial to regulate the AKT-ERK pathway in breast cancer. ACS Omega 3, 8317–8328 (2018). https://doi.org/10.1021/acsomega.7b0134710.1021/acsomega.7b01347 ↗
55. J. Yang, P. Xiao, J. Sun, L. Guo, Anticancer effects of kaempferol in A375 human malignant melanoma cells are mediated via induction of apoptosis, cell cycle arrest, inhibition of cell migration and downregulation of m-TOR/PI3K/AKT pathway. J. BUON 23, 218–223 (2018)
56. T. Mosmann, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55–63 (1983). https://doi.org/10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
57. G. Karthikkeyan, R. Pervaje, S.K. Pervaje, T.S. Prasad, P.K. Modi, Prevention of MEK-ERK-1/2 hyper-activation underlines the neuroprotective effect of Glycyrrhiza glabra L. (Yashtimadhu) against rotenone-induced cellular and molecular aberrations. J. Ethnopharmacol. 274, 114025 (2021). https://doi.org/10.1016/j.jep.2021.11402510.1016/j.jep.2021.114025 ↗
58. M.A. Najar, A. Aravind, S. Dagamajalu, D. Sidransky, H. Ashktorab, D.T. Smoot, H. Gowda, T.K. Prasad, P.K. Modi, A. Chatterjee, Hyperactivation of MEK/ERK pathway by Ca2+/calmodulin-dependent protein kinase kinase 2 promotes cellular proliferation by activating cyclin-dependent kinases and minichromosome maintenance protein in gastric cancer cells. Mol. Carcinog. 60, 769–783 (2021). https://doi.org/10.1002/mc.2334310.1002/mc.23343 ↗
59. S.R. Pavan, J. Venkatesan, A. Prabhu, Anticancer activity of silver nanoparticles from the aqueous extract of Dictyota ciliolata on non-small cell lung cancer cells. J. Drug. Deliv. Sci. Tech. 74, 103525 (2022). https://doi.org/10.1016/j.jddst.2022.10352510.1016/j.jddst.2022.103525 ↗
60. B. Bose, S. Kapoor, U. Sen, D. Chaudhury, P.S. Shenoy, Assessment of oxidative damage in the primary mouse ocular surface cells/stem cells in response to ultraviolet-C (UV-C) damage. J. Vis. Exp. (2020). https://doi.org/10.3791/5992410.3791/59924 ↗
61. A.P. Sajida, Anti-angiogenic, apoptotic and matrix metalloproteinase inhibitory activity of Withania somnifera (ashwagandha) on lung adenocarcinoma cells. Phytomedicine 90, 153639 (2021). https://doi.org/10.1016/j.phymed.2021.15363910.1016/j.phymed.2021.153639 ↗
62. G. Karthikkeyan, S.K. Behera, S.S. Upadhyay, R. Pervaje, T.S. Prasad, P.K. Modi, Metabolomics analysis highlights Yashtimadhu (Glycyrrhiza glabra L.)-mediated neuroprotection in a rotenone-induced cellular model of Parkinson’s disease by restoring the mTORC1-AMPK1 axis in autophagic regulation. Phyto. Ther. Res. 36, 2207 (2022). https://doi.org/10.1002/ptr.744910.1002/ptr.7449 ↗